Director of Immuno-oncology with expertise in T cell biology, drug discovery and precision medicine. Successful experience in progressing immuno-oncology drug candidates from early research to IND filing. 9+ years leading drug discovery programs (antibodies, small molecules & CAR-T); 5 years managing cross-functional teams (20+ people); 5 years recruiting & managing Ph.D./non-Ph.D. level direct reports. Lead inventor on 2 patents: (1) a patient stratification biomarker for AstraZeneca, now tested in 2 phase II clinical trials; (2) the discovery and development of a key I-O drug in the pipeline of Pfizer. 3 first-author publications (Cancer Cell, Cell Reports, Nature Reviews Drug Discovery) with 500+ citations, 3 oral presentations in AACR conferences (1,500+ audience), 5 grants ($1M+), 7 research awards.
Immunotherapy, personalised cancer therapies, precision medicine, epigenetics, CRISPR, synthetic lethality, in vivo models, kinase inhibitors, biomarkers, clinical trials, project management.